NCT04971226 2026-04-06
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
Novartis
Children's Oncology Group
Takeda
Sir Mortimer B. Davis - Jewish General Hospital
Helsinki University Central Hospital
Gruppo Italiano Malattie EMatologiche dell'Adulto
Il-Yang Pharm. Co., Ltd.